COMPOSITIONS FOR BIOLOGICAL SYSTEMS AND METHODS FOR PREPARING AND USING THE SAME

• US 20170354683A1
• Filed: 06/10/2017
• Published: 12/14/2017
• Est. Priority Date: 06/13/2016
• Status: Active Grant

• Current Assignee: Smart Surgical, Inc.
• Original Assignee: Smart Surgical, Inc.
• Inventors: JONES, CHRISTOPHER D., Quintanar, Nathan, Patel, Roshan
• Granted Patent: US 10,426,796 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/15 Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/20 containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 47/42 Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein oligopeptides having up to five amino acids A61K47/183; polyamino acids A61K47/34
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C12N 2500/34 Sugars
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 5/0037 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 5/0665 Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood

Abstract

A composition for influencing biological growth includes a solution having a first volume and having low pH fluid base including dextrose, and albumin, wherein the concentration of albumin in the solution is between about 10 mg/ml and about 150 mg/ml.

Claims

1. A composition for influencing biological growth comprising:

a solution having a first volume and comprising;

a low pH fluid base comprising dextrose; and

albumin, wherein the concentration of albumin in the solution is between about 10 mg/ml and about 150 mg/ml.

2. The composition of claim 1, wherein the pH of the composition is between 5.0 and 7.4.

3. The composition of claim 1, wherein the pH of the composition is between 4.1 and 7.2.

4. The composition of claim 1, wherein the pH of the composition is between 4.1 and 6.2.

5. The composition of claim 1, wherein the pH of the composition is between 5.0 and 6.2.

7. The composition of claim 1, further comprising sodium bicarbonate.

8. The composition of claim 1, further comprising calcium bicarbonate.

9. The composition of claim 1, wherein the albumin is from commercially available human serum.

10. The composition of claim 1, wherein the albumin is from donor-derived serum.

11. The composition of claim 1, wherein the albumin is from human umbilical cord blood.

12. The composition of claim 1, wherein the concentration of albumin in the solution is between about 10 mg/ml and about 120 mg/ml.

13. The composition of claim 1, wherein the concentration of albumin in the solution is between about 50 mg/ml and about 150 mg/ml.

15. The composition of claim 1, wherein the concentration of albumin in the solution is between about 105 mg/ml and about 150 mg/ml.

16. The composition of claim 1, wherein the composition does not contain dimethyl sulfoxide (DMSO).

17. The composition of claim 1, wherein the low pH fluid base further comprises dextran.

18. The composition of claim 1, wherein the low pH fluid base further comprises dimethyl sulfoxide (DMSO).

19. The composition of claim 1, wherein the low pH fluid base further comprises CryoGold™

or the equivalent.

20. The composition of claim 1, further comprising stem cells.

21. The composition of claim 20, wherein the stem cells consist of non-expanded cell populations.

22. The composition of claim 20, wherein the stem cells comprise hematopoietic stem cells (HSC).

23. The composition of claim 20, wherein the stem cells comprise mesenchymal stem cells (MSC).

24. The composition of claim 1, further comprising live mononuclear cells.

25. The composition of claim 24, wherein the composition comprises between about 100,000 and about 75 million live mononuclear cells per ml.

27. The composition of claim 24, wherein the composition comprises between about 10 million and about 30 million live mononuclear cells per ml.

29. The composition of claim 24, wherein the composition comprises between about 2.5 million and about 10.2 million live mononuclear cells per ml.

31. The composition of claim 24, wherein the mononuclear cells are derived only from umbilical cord blood of a single donor.

32. The composition of claim 1, further comprising one or more bioactive agents.

33. The composition of claim 32, wherein the one or more bioactive agents comprise one or more cytokines.

35. The composition of claim 32, wherein the one or more bioactive agents comprise one or more growth factors.

40. The composition of claim 32, wherein the one or more bioactive agents are selected from the group consisting of macrophage inflammatory protein alpha (MIP-1α

), macrophage inflammatory protein beta (MIP-1β

), interferon gamma-induced protein 10 (IP-10), interleukin 1 Beta (IL-1β

), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 9 (IL-9), interleukin 10 (IL-10), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), interleukin 17 (IL-17), interleukin 18 (IL-18), interleukin 21 (IL-21), interleukin 22 (IL-22), interleukin 23 (IL-23), interleukin 27 (IL-27), interleukin 31 (IL-31), interferon alpha (INFα

), a lymphokine, granulocyte macrophage colony stimulating factor (GM-CSF), stem cell factor (KL), tumor necrosis factor alpha (TNF-α

), vascular endothelial growth factor (VEGF), nerve growth factor, platelet-derived growth factor (PDGF), fibroblast growth factor 2 (FGF-2), epidermal growth factor (EGF), keratinocyte growth factor, transforming growth factor (TGF), insulin-like growth factor, des(1-3)-IGF-I (brain IGF-I), neurotrophin-3 (NT-3), brain-derived neurotrophic factor (BDNF), eotaxin, CXC ligand 1 (GROα

), interleukin 1 receptor antagonist (IL-1RA), interleukin 1 alpha (IL-1α

), leukemia inhibitory factor (LIF), placental growth factor (PLGF), chemokine ligand 5 (RANTES), stem cell factor (SCF), stromal cell derived factor (SDF1α

), and tumor necrosis factor (TNF β

).

6. (canceled)

14. (canceled)

26. (canceled)

28. (canceled)

30. (canceled)

34. (canceled)

36-39. -39. (canceled)

41-216. -216. (canceled)